SMITH AND NEPHEW
BiotechSMITH AND NEPHEW is a biotechnology company focused on Cardiovascular, Oncology, Neurology.
SMITH AND NEPHEW's Key Drugs
SMITH AND NEPHEW's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SMITH AND NEPHEW's Recent FDA Approvals
New NDA/BLA approvals for SMITH AND NEPHEW over the last two years — novel drugs only, excluding generics and label supplements.
SMITH AND NEPHEW's Therapeutic Areas
SMITH AND NEPHEW's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Oncology, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SMITH AND NEPHEW's Top Competitors
SMITH AND NEPHEW's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Takeda, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SMITH AND NEPHEW Pipeline Snapshot
Active clinical trials for SMITH AND NEPHEW across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1965-06-04
- Latest
- 2019-08-26
- Applications
- 44